Originally published by our sister publication Specialty Pharmacy Continuum
By SPC Staff
Biogen announced on Jan. 31 that it would abandon the development and commercialization of aducanumab (Aduhelm), its controversial Alzheimer’s disease (AD) drug, citing the need to shift resources to other treatments for the brain disorder.